Aliases & Classifications for Scotoma

About this section

Aliases & Descriptions for Scotoma:

Name: Scotoma 11 27 13
Generalized Visual Field Contraction or Constriction 11
Sector or Arcuate Visual Field Defects 11
Enlarged Paracaecal Scotoma 11
 
Scotoma of Blind Spot Area 11
Blind Spot Area Scotoma 11
Enlarged Angioscotoma 11
Enlarged Blind Spot 11

Classifications:



External Ids:

Disease Ontology11 DOID:9335
SNOMED-CT62 193673000, 33970004

Summaries for Scotoma

About this section
Wikipedia:71 A scotoma (Greek σκότος/skótos, darkness; plural: scotomas or scotomata) is an area... more...

MalaCards based summary: Scotoma, also known as generalized visual field contraction or constriction, is related to optic atrophy 1 and migraine, familial hemiplegic, 2. An important gene associated with Scotoma is KCNMA1 (Potassium Calcium-Activated Channel Subfamily M Alpha 1), and among its related pathways are Metabolism of fat-soluble vitamins and the visual cycle I (vertebrates). Affiliated tissues include eye, testes and pituitary.

Related Diseases for Scotoma

About this section

Diseases related to Scotoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 64)
idRelated DiseaseScoreTop Affiliating Genes
1optic atrophy 110.9
2migraine, familial hemiplegic, 210.7
3migraine, familial hemiplegic, 310.7
4optic atrophy 710.7
5migraine, familial hemiplegic, 110.7
6leber optic atrophy10.7
7birdshot chorioretinopathy10.7
8familial hemiplegic migraine10.7
9retinitis10.2
10cone-rod dystrophy 310.1ABCA4, KCNMA1
11allergic contact dermatitis of eyelid10.1MT-ND4, OPA1
12alopecia, androgenetic, 210.0MT-ND4, OPA1, TMEM126A
13hypopigmentation of eyelid10.0MT-ND4, SNCA
14autoimmune gastrointestinal dysmotility10.0OPA1, TMEM126A
15lipoprotein lipase deficiency10.0MT-ND4, SNCA
16growth hormone deficiency, isolated partial10.0MT-ND4, SNCA
17hypertrichosis terminalis, generalized, with or without gingival hyperplasia9.9ABCA4, RDH5
18neuritis9.9
19spinocerebellar ataxia, autosomal recessive 159.8MT-ND4, OPA1, SNCA, TMEM126A
20macular holes9.8
21headache9.8
22systemic lupus erythematosus9.7
23stargardt disease9.7
24cataract9.7
25amblyopia9.7
26open-angle glaucoma9.7
27choroiditis9.7
28uveitis9.7
29cerebritis9.7
30strabismus9.7
31adenoma9.7
32lupus erythematosus9.7
33anterior uveitis9.7
34aneurysm9.7
35pituitary tumors9.7
36hepatitis c virus9.6
37hepatitis9.6
38retinal vein occlusion9.6
39sinusitis9.6
40cytomegalovirus retinitis9.6
41migraine with aura9.6
42neuroretinitis9.6
43endocarditis9.6
44astigmatism9.6
45myopia9.6
46optic neuritis9.6
47hepatitis c9.6
48melanoma9.6
49central retinal vein occlusion9.6
50chromophobe adenoma9.6

Graphical network of the top 20 diseases related to Scotoma:



Diseases related to scotoma

Symptoms & Phenotypes for Scotoma

About this section

Drugs & Therapeutics for Scotoma

About this section

Drugs for Scotoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RanibizumabapprovedPhase 3, Phase 1, Phase 2486347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
2
Bevacizumabapproved, investigationalPhase 32020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
3Angiogenesis InhibitorsPhase 3, Phase 1, Phase 24257
4Angiogenesis Modulating AgentsPhase 3, Phase 1, Phase 24185
5Omega 3 Fatty AcidNutraceuticalPhase 31018
6Idebenoneapproved, investigationalPhase 22158186-27-9
7Trace ElementsPhase 26001
8Protective AgentsPhase 27443
9UbiquinonePhase 2145
10MicronutrientsPhase 26001
11
ImidaclopridPhase 2187105827-78-986418
Synonyms:
(e)-imidacloprid
(z)-imidacloprid
1-((6-Chloro-3-pyridyl)methyl)-N-nitro-2-imidazolidinimine
1-(2-Chloro-5-pyridylmethyl)-2-(nitroimino)imidazolidine
1-[(6-Chloro-3-pyridinyl)methyl]-4,5-dihydro-N-nitro-1H-imidazol-2-amine, 9CI
Admire
Advantage
Advantage flea adulticide
Bayer brand of imidacloprid
 
Confidor
Confidor 200 SL
Confidor SL
Gaucho
Imidacloprid (old RN)
Imidacloprid [iso]
Merit
Merit (insecticide)
Premise 75
Provado
12AntioxidantsPhase 23050
13
Latanoprostapproved, investigational198130209-82-45282380, 5311221
Synonyms:
130209-82-4
AC1NSK8Q
AR-202
Ambap130209-82-4
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
Catioprost
D00356
HMS2051H11
HMS2089J17
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Jsp001835
L1167_SIGMA
Latanoprost
Latanoprost (JAN/USAN/INN)
Latanoprostum
MLS000759468
MLS001424106
 
MolPort-003-942-862
Nova-21027
PHXA-41
PhXA 41
PhXA34 [as 15(R,S)-isomer]
PhXA41
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA-41
XA41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
latanoprost
latanoprost free acid
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
14
Luteinapproved, nutraceutical71127-40-26433159, 5368396
Synonyms:
(3R,3'R)-beta,beta-Carotene-3,3'-Diol, Lutein
(3R,3'R,6'R)-Lutein
(3R,3'R,6S)-4,5-Didehydro-5,6-Dihydro-beta,beta-Carotene-3,3'-Diol
3,3'-Dihydroxy-alpha-carotene
4,5-Didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol
All-trans-(+)-Xanthophyll
All-trans-Lutein
All-trans-Xanthophyll
 
Bo-Xan
Lutein
Lutein ester
Luteine
Phylloxanthin
Vegetable lutein
Vegetable luteol
beta,epsilon-Carotene-3,3'-diol
trans-Lutein
15
Diminazeneexperimental3536-71-0
Synonyms:
1,3-TRIS-(4'AMIDINOPHENYL)TRIAZINE
4,4'-(1-Triazene-1,3-diyl)bis-benzenecarboximidamide
 
4,4'-(Diazoamino)benzamidine
Diminazene aceturate
Diminazine
Diminazine aceturate
16Diminazene aceturate10
17Antiprotozoal Agents2051
18Antiparasitic Agents2199
19Anti-Infective Agents22062
20Liver Extracts4067
21Tissue Plasminogen Activator238
22Fibrinolytic Agents2388
23Plasminogen242

Interventional clinical trials:

(show all 35)
idNameStatusNCT IDPhase
1Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis TherapyUnknown statusNCT01255774Phase 3
2Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic LesionsUnknown statusNCT01418820Phase 2, Phase 3
3Bevacizumab Versus Ranibizumab for Diabetic RetinopathyCompletedNCT00545870Phase 3
4A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular AdhesionCompletedNCT01889251Phase 3
5Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).TerminatedNCT00987129Phase 3
6Scotoma Reduction in AMD Patients Treated With RanibizumabCompletedNCT00467935Phase 1, Phase 2
7Evaluation of Eye Movement Tracking Systems for Visual RehabilitationCompletedNCT00013429Phase 2
8Low Vision Study Comparing EV Training vs. CCTV for AMD RehabilitationCompletedNCT00971464Phase 2
9Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)CompletedNCT00504400Phase 2
10Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic NeuropathyCompletedNCT00747487Phase 2
11Gene Therapy for Achromatopsia (CNGB3)RecruitingNCT03001310Phase 1, Phase 2
12Visuomotor Rehabilitation TrainingCompletedNCT01691027Early Phase 1
13A Study to Determine the Location of the Blind Spot and the Macula-disc Centre Distance on a Fundus PhotographCompletedNCT01843582
14The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration TherapyCompletedNCT00921427Early Phase 1
15Detection of Topographic Residual Acuity in Patients With Age Related Macular DegenerationCompletedNCT00329277
16Sparing of the Fovea in Geographic Atrophy ProgressionCompletedNCT02332343
17Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular DegenerationCompletedNCT00879671
18A Clinical Study of Fundus Findings in Toxaemia of PregnancyCompletedNCT03076619
19Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole SurgeryCompletedNCT00419185
20Age-related Normative Values for the Octopus 900 PerimeterCompletedNCT01518686
21Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane SurgeryCompletedNCT03045367
22Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV)RecruitingNCT02829606
23Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular OedemaRecruitingNCT02457884
24Effect of the Membrane Blue Dual® Dye on the Retinal Sensitivity in Macular Hole SurgeryRecruitingNCT02894424
25Telescope Exchange StudyRecruitingNCT03011554
26Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the RetinaRecruitingNCT02088151
27Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial FibrillationRecruitingNCT02424110
28Oxidative Stress and Endothelial Function in Pregnancy ComplicationsRecruitingNCT02603913
29Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma PatientsActive, not recruitingNCT00902109
30Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX PerimeterActive, not recruitingNCT01068938
31Clinical Study of LPI With Different Laser WavelengthsActive, not recruitingNCT02901730
32Clinical Study of LPI on Different Sites of IrisActive, not recruitingNCT02870504
33Treatment Trial for Acute Central Serous ChorioretinopathyEnrolling by invitationNCT02784665
34Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular DegenerationEnrolling by invitationNCT02747368
35Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration ComplicationsNot yet recruitingNCT02557451

Search NIH Clinical Center for Scotoma

Genetic Tests for Scotoma

About this section

Genetic tests related to Scotoma:

id Genetic test Affiliating Genes
1 Scotoma27

Anatomical Context for Scotoma

About this section

MalaCards organs/tissues related to Scotoma:

36
Eye, Testes, Pituitary, Cortex, Occipital lobe, Retina, Brain

Publications for Scotoma

About this section

Articles related to Scotoma:

(show top 50)    (show all 216)
idTitleAuthorsYear
1
Scotoma Visibility and Reading Rate with Bilateral Central Scotomas. (28030516)
2016
2
MAPPING THE DENSE SCOTOMA AND ITS ENLARGEMENT IN STARGARDT DISEASE. (26909568)
2016
3
Characteristics of the preferred retinal loci of better and worse seeing eyes of patients with a central scotoma. (27769327)
2016
4
Progressing Scintillating Scotoma Captured on Automated Visual Field Testing. (26854039)
2016
5
The Effects of Nocturnal Dip and Blood Pressure Variability on Paracentral Scotoma in Early Open-Angle Glaucoma. (27128963)
2016
6
Optic Disk Pit with Sudden Central Visual Field Scotoma. (27872777)
2016
7
Assessing the GOANNA Visual Field Algorithm Using Artificial Scotoma Generation on Human Observers. (27622080)
2016
8
Comparison of retinal vessel diameter between open-angle glaucoma patients with initial parafoveal scotoma and peripheral nasal step. (27916714)
2016
9
Structure-Function Relationship in Glaucoma Patients With Parafoveal Versus Peripheral Nasal Scotoma. (26848881)
2016
10
Long-lasting, dense scotoma under light-adapted conditions in patient with multiple evanescent white dot syndrome. (26678272)
2015
11
Clinical Clues to Predict the Presence of Parafoveal Scotoma on Humphrey 10-2 Visual Field Using a Humphrey 24-2 Visual Field. (26476213)
2015
12
Comparison of Risk Factors for Initial Central Scotoma versus Initial Peripheral Scotoma in Normal-tension Glaucoma. (25829826)
2015
13
Scotoma analysis of 10-2 visual field testing with a red target in screening for hydroxychloroquine retinopathy. (26316692)
2015
14
Microperimetry biofeedback training in a patient with bilateral myopic macular degeneration with central scotoma. (26265646)
2015
15
Random word recognition chart helps scotoma assessment in low vision. (25946100)
2015
16
Optimal point of fixation to faces for vision with a simulated central scotoma. (26326621)
2015
17
fMRI of the rod scotoma elucidates cortical rod pathways and implications for lesion measurements. (25848028)
2015
18
Stop before you saccade: Looking into an artificial peripheral scotoma. (26067525)
2015
19
Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy. (26060390)
2015
20
Size of the foveal blue scotoma related to the shape of the foveal pit but not to macular pigment. (25449158)
2015
21
Anatomical attributes of the optic nerve head in eyes with parafoveal scotoma in normal tension glaucoma. (24595065)
2014
22
Confusion Between Bitemporal Hemianopia and Cecocentral Scotoma: Reply. (25313790)
2014
23
Xanthic scotoma. (25256032)
2014
24
Comment on "Central scotoma and 'muddled thinking' as migraine aura" by Daroff. (24045572)
2014
25
Reading with peripheral vision: a comparison of reading dynamic scrolling and static text with a simulated central scotoma. (24680772)
2014
26
Central scotoma and 'muddled thinking' as migraine aura. (24045570)
2014
27
Adaptation to a simulated central scotoma during visual search training. (24456805)
2014
28
Confusion Between Bitemporal Hemianopia and Cecocentral Scotoma. (25313789)
2014
29
Paracentral scotoma in glaucoma detected by 10-2 but not by 24-2 perimetry. (24442888)
2014
30
Parafoveal scotoma progression in glaucoma: humphrey 10-2 versus 24-2 visual field analysis. (23697959)
2013
31
A behavioral task for the validation of a gaze-contingent simulated scotoma. (23526257)
2013
32
Scotomas in molecular virology and epidemiology of hepatitis C virus. (24307785)
2013
33
Central scotoma without prodromal illness caused by Bartonella henselae neuroretinitis. (23481153)
2013
34
Fixation stability and scotoma mapping for patients with low vision. (23334309)
2013
35
Arcuate scotoma associated with traction at the optic disc. (23449516)
2013
36
Measurement of macular ganglion cell layer and circumpapillary retinal nerve fiber layer to detect paracentral scotoma in early glaucoma. (23620092)
2013
37
Initial central scotomas vs peripheral scotomas in normal-tension glaucoma: clinical characteristics and progression rates. (24357841)
2013
38
Rehabilitative approach in patients with ring scotoma. (24093190)
2013
39
The effect of strabismus on object detection in the ring scotoma of a monocular bioptic telescope. (23639041)
2013
40
Macular structure parameters as an automated indicator of paracentral scotoma in early glaucoma. (23972895)
2013
41
Characteristics of optic disc morphology in glaucoma patients with parafoveal scotoma compared to peripheral scotoma. (22714895)
2012
42
Patient awareness of binocular central scotoma in age-related macular degeneration. (22863789)
2012
43
FUNDUS AUTOFLUORESCENCE IMAGING IN A PATIENT WITH RAPIDLY DEVELOPING SCOTOMA. (23293707)
2012
44
Decreased vision and junctional scotoma from pituicytoma. (22740829)
2012
45
Recommendations for the treatment of hypertension in the elderly and very elderly--a scotoma within international guidelines. (22573500)
2012
46
Lack of spatial remapping of the visual field surrounding a monocular scotoma. (21682767)
2012
47
Opposite effects of perceptual and working memory load on perceptual filling-in of an artificial scotoma. (24168648)
2012
48
Chronic disabling pain: a scotoma in the eye of both pain medicine and rehabilitation in Europe. (23159955)
2012
49
Facial pain, scotomas and hemihypaesthesia as presenting symptoms of type A aortic dissection in a patient with migraine with aura. (22407662)
2012
50
Treating our societal scotoma: the case for investing in geriatrics, our nation's future, and our patients. (22547475)
2012

Variations for Scotoma

About this section

Expression for genes affiliated with Scotoma

About this section
Search GEO for disease gene expression data for Scotoma.

Pathways for genes affiliated with Scotoma

About this section

GO Terms for genes affiliated with Scotoma

About this section

Cellular components related to Scotoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial respiratory chain complex IGO:000574710.4MT-ND4, SNCA
2mitochondrionGO:00057397.7MT-ND4, OPA1, SNCA, TMEM126A, VARS

Biological processes related to Scotoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1retinoid metabolic processGO:00015239.8ABCA4, CYP4V2, RDH5
2agingGO:00075689.6MT-ND4, OPA1, SNCA
3oxidation-reduction processGO:00551149.5CYP4V2, MT-ND4, RDH5, SNCA
4response to stimulusGO:00508969.0ABCA4, CYP4V2, OPA1, RDH5
5visual perceptionGO:00076018.3ABCA4, CYP4V2, OPA1, RDH5

Molecular functions related to Scotoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1oxidoreductase activityGO:00164918.8CYP4V2, MT-ND4, RDH5, SNCA

Sources for Scotoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet